ANAB vs. MLYS, DNTH, NRIX, NUVB, WVE, BCYC, PAHC, SVRA, IRON, and AUPH
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Mineralys Therapeutics (MLYS), Dianthus Therapeutics (DNTH), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB), Wave Life Sciences (WVE), Bicycle Therapeutics (BCYC), Phibro Animal Health (PAHC), Savara (SVRA), Disc Medicine (IRON), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical preparations" industry.
Mineralys Therapeutics (NASDAQ:MLYS) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
84.5% of Mineralys Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 33.7% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Mineralys Therapeutics currently has a consensus target price of $33.50, indicating a potential upside of 156.51%. AnaptysBio has a consensus target price of $46.38, indicating a potential upside of 83.59%. Given AnaptysBio's stronger consensus rating and higher probable upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than AnaptysBio.
Mineralys Therapeutics has a net margin of 0.00% compared to Mineralys Therapeutics' net margin of -711.17%. AnaptysBio's return on equity of -32.48% beat Mineralys Therapeutics' return on equity.
AnaptysBio received 341 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 65.61% of users gave AnaptysBio an outperform vote.
Mineralys Therapeutics has higher earnings, but lower revenue than AnaptysBio. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
In the previous week, AnaptysBio had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 18 mentions for AnaptysBio and 10 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.29 beat AnaptysBio's score of 0.21 indicating that AnaptysBio is being referred to more favorably in the news media.
Mineralys Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500.
Summary
Mineralys Therapeutics beats AnaptysBio on 10 of the 17 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
